Trial Profile
A Prospective Study to Estimate the Incidence of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Infants and Young Children in Sub-Saharan Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs GSK 257049 (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 May 2020 Status changed from recruiting to active, no longer recruiting.
- 20 May 2019 Planned End Date changed from 30 May 2022 to 20 Jul 2022.